William Carson Acquires 4,115 Shares of Annexon (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) Director William Carson bought 4,115 shares of the stock in a transaction dated Tuesday, December 30th. The stock was purchased at an average price of $5.02 per share, with a total value of $20,657.30. Following the purchase, the director owned 54,405 shares in the company, valued at $273,113.10. This trade represents a 8.18% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Annexon Trading Down 6.6%

ANNX opened at $4.69 on Friday. The company has a market cap of $561.06 million, a price-to-earnings ratio of -3.33 and a beta of 1.19. The stock has a fifty day simple moving average of $4.16 and a two-hundred day simple moving average of $3.14. Annexon, Inc. has a 12-month low of $1.28 and a 12-month high of $5.66.

Annexon (NASDAQ:ANNX) last announced its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). On average, analysts predict that Annexon, Inc. will post -0.96 EPS for the current year.

Institutional Investors Weigh In On Annexon

Institutional investors and hedge funds have recently made changes to their positions in the company. Matauro LLC purchased a new position in Annexon in the 2nd quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Annexon in the second quarter worth $29,000. 49 Wealth Management LLC bought a new position in shares of Annexon during the second quarter valued at $29,000. CIBC Bancorp USA Inc. bought a new position in shares of Annexon during the third quarter valued at $31,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Annexon during the second quarter valued at $32,000.

Wall Street Analyst Weigh In

ANNX has been the subject of a number of analyst reports. Wells Fargo & Company raised their target price on shares of Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, October 8th. Finally, Chardan Capital started coverage on Annexon in a research note on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price objective for the company. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.